AVEO AVEO Pharmaceuticals Inc.

4.28
-0.02  -0%
Previous Close 4.3
Open 4.15
Price To Book 4.65
Market Cap 68,825,036
Shares 16,080,616
Volume 293,079
Short Ratio
Av. Daily Volume 224,980
Stock charts supplied by TradingView

NewsSee all news

  1. AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis

    AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO's potent hepatocyte growth factor (HGF)

  2. AVEO Oncology Reports Full Year 2019 Financial Results and Provides Business Update

    AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2019 and provided a business update. "The coming months will be an important period for AVEO, with filing of a New Drug

  3. AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split

    AVEO Oncology (NASDAQ:AVEO) today announced that it will effect a 1-for-10 reverse stock split of its common stock that will be effective as of 5:00 p.m. Eastern Time today, February 19, 2020. AVEO's common stock will

  4. AVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer in the British Journal of Cancer

    AVEO Oncology (NASDAQ:AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company's vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in patients

  5. AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

    - Data Presented at the 2020 ASCO GI Cancers Symposium - AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO's

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 2021.
Ficlatuzumab and cetuximab
Head and neck squamous cell carcinoma (HNSCC)
Phase 2 final data presented at ESMO 2019.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
Ficlatuzumab
EGFR-mutated Non-small cell lung cancer (NSCLC)
NDA to be filed in 1Q 2020. Will withdraw if overall survival data in June 2020 yields an OS HR above 1.00.
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 2 trial discontinued due to COVID-19.
Ficlatuzumab and cytarabine
Acute myeloid leukemia (AML)
Phase 1/2 trial initiation announced September 30, 2019.
FOTIVDA (Tivozanib) and IMFINZI (Durvalumab)
Hepatocellular carcinoma (HCC)
Phase 1b data noted 29% partial response (PR) rate - January 27, 2020.
Ficlatuzumab and nab-paclitaxel
Pancreatic ductal adenocarcinoma (PDAC)

Latest News

  1. AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis

    AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO's potent hepatocyte growth factor (HGF)

  2. AVEO Oncology Reports Full Year 2019 Financial Results and Provides Business Update

    AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2019 and provided a business update. "The coming months will be an important period for AVEO, with filing of a New Drug

  3. AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split

    AVEO Oncology (NASDAQ:AVEO) today announced that it will effect a 1-for-10 reverse stock split of its common stock that will be effective as of 5:00 p.m. Eastern Time today, February 19, 2020. AVEO's common stock will

  4. AVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer in the British Journal of Cancer

    AVEO Oncology (NASDAQ:AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company's vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in patients

  5. AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

    - Data Presented at the 2020 ASCO GI Cancers Symposium - AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO's

  6. AVEO Announces Appointment of Erick J. Lucera as Chief Financial Officer

    AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Erick Lucera as chief financial officer. Mr. Lucera will be responsible for managing all aspects of the Company's financial and accounting functions. "It

  7. AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

    AVEO Oncology (NASDAQ:AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology. TIVO-3 is the Company's Phase 3 randomized, controlled, multi-center,

  8. AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference

    AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2019 at

  9. AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors

    AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical and

  10. AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

    - Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC - - Outcomes Favor Tivozanib in Patients Previously Treated With

  11. AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update

    AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. "This quarter we have made meaningful progress toward our goal of bringing

  12. AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML

    AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO's potent hepatocyte growth factor (HGF) inhibitory

  13. AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma

    - NDA Filing Planned for 1Q20 for Relapsed/Refractory RCC – - Company Plans Final OS Analysis in 2Q20 - AVEO Oncology (NASDAQ:AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug

  14. AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

    AVEO Oncology (NASDAQ:AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company's once-daily, potent and selective

  15. AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at

  16. Thinking about buying stock in AVEO Pharmaceuticals, CAN-FITE Biopharma, Francesca's, AT&T, or Tilray?

    NEW YORK, Sept. 10, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVEO, CANF, FRAN, T, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  17. AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

    - 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm - - Company Plans to Discuss Updated Results with FDA - - AVEO to Host Conference Call Today at 8:00 am Eastern Time - AVEO Oncology